News and Announcements
Analytica Granted Patent Protection for PeriCoach® in Australia
- Published May 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Analytica (ASX: ALT) has been granted patent protection in Australia for the PeriCoach® System’s unique pelvic floor force sensing technology.
KEY TAKEAWAYS:
- Patents on the PeriCoach force sensors have now been issue in China, Japan and Australia.
- With patents pending in US, India, Brazil and Europe.
- The patent has a term of 20 years from 9 January 2012.
- It has remained a top priority to ensure that PeriCoach becomes a global product, therefor Analytica has maintained its investment in intellectual protection in major markets around the world.
- The intellectual property strategy remains to secure protection in key geographies that have ageing populations, with increased awareness of urinary incontinence, and growing treatment solutions.
Analytica CEO Geoff Daly said – “Continuing to develop and secure our intellectual property in key global markets is important to licencing partners, as it provides them the freedom to take our Australian inventions to the world. Australia is an attractive location to conduct R&D and most of Analytica’s research takes place here. The Federal Government’s decision to maintain the R&D tax incentive provides welcome assurance that it will remain that way.”
Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.
PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
